News

Industry welcomes Myriad verdict
Enlarge image

RegulatoryGermanySwitzerland

Industry welcomes Myriad verdict

17.06.2013 - Industry organisations and biotech experts have welcomed the vote of the US Supreme Court to allow cDNA to be patented.

In a groundbreaking verdict, the nine judges of the highest Court of the United States said that DNA generally cannot be patented because it occurs in nature. However judge Clarence Thomas added that cDNA is made by man and thus can be patented by biotech firms. 

The vote in the case Myriad Genetics vs the American Society for Pathology is a well-balanced compromise.  Researchers had argued that Myriad Genetics’ current practice to prohibit any isolation of BRCA1 and BRAC2 gene sequences predictive for breast or ovarian cancer hampered research and innovation. Companies and pharma organisations told European Biotechnology News, the verdict was good news for the industry as most biotech patents include claims on modified DNA sequences not occurring in nature. 

„Roche welcomes that the US Supreme Court confirmed that cDNA is patent-eligible“, a spokesman told EuroBiotechNews.„IP on our medicaments and diagnostics mostly is not based on naturally occurring DNA.“ Sigfried Throm from the German pharma association vfa confirmed: „The verdict does not affect drugs made by genetically engineering as they are systematically modified compared to their natural counterpart." Diagnostics expert Joerg Hollidt, CEO of IVD firms in.vent Diagnostica and DRDx said that the decision will foster patenting of cDNA and technology claims. "The decision cannot and will not stop the development of personalised medicine or personalised diagnostics“, stressed Hollidt. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/industry-welcomes-myriad-verdict.html

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto discussing a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS1.32 CHF30.69%
  • WILEX5.08 EUR17.32%
  • SYNGENTA339.90 CHF8.11%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • MEDIGENE10.26 EUR-6.39%
  • MOLOGEN4.85 EUR-1.82%

TOP

  • 4SC5.20 EUR306.2%
  • WILEX5.08 EUR77.6%
  • PAION2.86 EUR21.7%

FLOP

  • BIOTEST71.20 EUR-26.7%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.26 EUR-16.8%

TOP

  • SANTHERA98.00 CHF2362.3%
  • CYTOS1.32 CHF500.0%
  • WILEX5.08 EUR483.9%

FLOP

  • MOLOGEN4.85 EUR-56.0%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.30 EUR-27.7%

No liability assumed, Date: 04.05.2015